

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

MYLAN PHARMACEUTICALS INC.,  
Petitioner,

v.

SANOFI-AVENTIS DEUTSCHLAND GMBH,  
Patent Owner.

---

Case No. IPR2018-01675  
Patent No. 8,603,044

---

**PETITIONER MYLAN'S MOTION TO CORRECT**  
37 CFR §42.104(c)

## **1. Statement of requested relief**

Petitioner (“Mylan”) requests correction of the petition (Paper 2) at page 25 to reflect that the citation “EX1011, ¶165; cf. EX1002, 3:42-44 (describing threads may include part threads).” should read “EX1011, ¶165; cf. EX1002, 3:62-64 (describing threads may include part threads).” That is, the “42-44” should be “62-64”. Mylan believes that the accompanying exhibit (EX1037) provides adequate clarification for the record, but will submit a corrected petition if the Board prefers.

## **2. Reasons for relief**

This motion is timely filed pursuant to an email authorization from Andrew Kellogg. 37 CFR §42.2(“Board”)(1). The petition contains a typographical error that substitutes “42-44” for “62-64”. The accompanying parenthetical and textual context make the nature of the error self-evident: the citation identifies a sentence “In the illustrated embodiment the second thread 24 comprises a series of part threads rather than a complete thread.” in EX1002 (the involved patent of Patent Owner (“Sanofi”)) to support a discussion of a discontinuous helical rib in the petition. Mylan regrets the error, but does not believe citing the wrong lines in the correct column for parenthetically described text in Sanofi’s own patent creates any significant prejudice for Sanofi. Pursuant to the Board’s instruction (EX1036, 16:14-17-7), the parties conferred on filing a correction exhibit or paper, but despite discussing a variety of options could not agree on the scope of Sanofi’s

response to the correction. To the extent a further Sanofi response to the correction is deemed appropriate, the Board can set its own limits on the response.

### **3. Conclusion**

Mylan requests the Board to grant this motion and accept EX1037 as sufficient correction of the petition.

Date: 30 January 2019

/ Richard Torczon /  
Richard Torczon, Lead Counsel  
Reg. No. 34,448

## UPDATED EXHIBIT LIST

<u>Exhibit No.</u>	<u>Description</u>
1001	U.S. Patent 8,679,069, <i>Pen-Type Injector</i> (issued Mar. 25, 2014)
1002	U.S. Patent 8,603,044, <i>Pen-Type Injector</i> (issued Dec. 10, 2013)
1003	U.S. Patent 8,992,486, <i>Pen-Type Injector</i> (issued Mar. 31, 2015)
1004	U.S. Patent 9,526,844, <i>Pen-Type Injector</i> (issued Dec. 27, 2016)
1005	U.S. Patent 9,604,008, <i>Drive Mechanisms Suitable for Use in Drug Delivery Devices</i> (issued Mar. 28, 2017)
1006	File History for U.S. Patent 8,679,069
1007	File History for U.S. Patent 8,603,044
1008	File History for U.S. Patent 8,992,486
1009	File History for U.S. Patent 9,526,844
1010	File History for U.S. Patent. 9,604,008
1011	Expert Declaration of Karl Leinsing MSME, PE in Support of Petition for <i>Inter Partes</i> Review of U.S. Patent Nos. 8,679,069; 8,603,044; 8,992,486; 9,526,844 and 9,604,008

<b><u>Exhibit No.</u></b>	<b><u>Description</u></b>
1012	<i>Curriculum Vitae</i> of Karl Leinsing MSME,PE
1013	U.S. Patent 6,221,046 - A. Burroughs et al., “Recyclable Medication Dispensing Device” (issued Apr. 24, 2001)
1014	U.S. Patent 6,235,004 – S. Steinfeldt-Jensen & S. Hansen, “Injection Syringe” (issued May 22, 2001)
1015	U.S. Patent Application US 2002/0053578 A1 – C.S. Møller, “Injection Device” (pub’d May 2, 2002)
1016	U.S. Patent 6,932,794 B2 – L. Giambattista & A. Bendek, “Medication Delivery Pen” (issued Aug. 23, 2005)
1017	U.S. Patent 6,582,404 B1 – P.C. Klitgaard et al., “Dose Setting Limiter” (issued June 24, 2003)
1018	File History for U.S. Patent 6,582,404
1019	Plaintiffs’ Preliminary Claim Constructions and Preliminary Identification of Supporting Intrinsic and Extrinsic Evidence, <i>Sanofi-Aventis U.S. LLC v. Mylan GmbH</i> , No. 2:17-cv-09105 (D.N.J.) (filed Sep. 5 2018)
1020	U.S. Patent 4,865,591 – B. Sams, “Measured Dose Dispensing Device” (issued Sep. 12, 1989)
1021	U.S. Patent 6,248,095 B1 – L. Giambattista et al., “Low-cost Medication Delivery Pen” (issued June 19, 2001)

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.